TUCSON Symposium 2023

Synthetic Singleplex Image Generation for Multiplex-Brightfield Immunohistochemistry using Image-to-image Translation Methods

Multiplex-brightfield immunohistochemistry imaging(MPx) enables quantification of various biomarkers in tissue while retaining morphological and spatial information. Manual scoring of MPx is challenging, especially with co-localized biomarkers. Consequently, it requires unmixing methods to separate multiple-staining intensities and remix individual-staining intensity together with counterstain to become singleplex images(SPx). Pathologists confidently can read and score staining intensity on SPx. Nevertheless, to unmix MPx is challenging, especially when more than two-biomarkers co-localized. Conventional unmixing methods e.g.,color-deconvolution or Nonnegative-Matrix-Factorization remain limited and error prone to separate staining intensities of co-localized biomarkers in membrane or nuclear-subcellular compartments. Here, we exploit advances in generative-adversarial networks(GANs), especially of unpaired image-to-image translation using CycleGAN to generate synthetic SPx from MPx for pathologists’ read and scores.

Analytical Performance of a Next Generation Sequencing (NGS) Assay for the Detection of Tumor Variants in Circulating Tumor (ct)DNA for use in the Detection of Early Molecular Response (EMR) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

In this Poster, the Authors present the results of the analytical validation studies for the AVENIO Oncology Assay Non-Hodgkin Lymphoma Test (AOA NHL Test).

An observational cohort study investigating the association between artificial intelligence- (AI) assisted tumor AREG and EREG immunohistochemistry (IHC) and outcomes from anti-EGFR therapy during the routine management of metastatic colorectal cancer (mCRC)

AREG and EREG are ligands of EGFR overexpressed by a subset of colorectal cancers (CRCs). Tumor AREG/EREG expression predicted benefit from anti-EGFR therapy in a previous retrospective analysis of the PICCOLO trial (second-line irinotecan ± panitumumab). This study sought to validate these findings in metastatic CRC patients who received anti-EGFR therapy during routine care.

External site

TUCSON Symposium 2023